Back to top
more

Orthofix Medical (OFIX)

(Delayed Data from NSDQ)

$12.54 USD

12.54
539,742

+0.23 (1.87%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $12.53 -0.01 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Orthofix (OFIX) Launches Limb Lengthening System in US & UK

by Zacks Equity Research

With FITBONE, Orthofix (OFIX) claims itself to be the only orthopedic company that offers a comprehensive portfolio of both internal and external fixation solutions for limb reconstruction.

Zacks Equity Research

Orthofix (OFIX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 247.62% and 29.28%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in Pharmaceutical segment.

Zacks Equity Research

What's in Store for Becton, Dickinson's (BDX) Q4 Earnings?

by Zacks Equity Research

Becton, Dickinson's (BDX) fiscal fourth-quarter results likely to reflect robust performance at BD Life Sciences.

Zacks Equity Research

Orthofix (OFIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Orthofix (OFIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Orthofix (OFIX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 26.25% and 35.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Orthofix (OFIX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Orthofix (OFIX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Orthofix JuniOrtho Plating System Gets Regulatory Clearances

by Zacks Equity Research

Orthofix (OFIX) rides high on dual regulatory clearances for its deformity correction system, thus solidifying its pediatric orthopedics portfolio.

Zacks Equity Research

Orthofix (OFIX) Misses Q1 Earnings Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of -18.18% and 0.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

Coronavirus Hits Elective Procedures: 3 MedTech Stocks to Avoid

by Trina Mukherjee

Amid the pandemonium on the account of coronavirus, we look into three stocks that have been struggling to cope with the scenario.

Zacks Equity Research

Orthofix Supports FDA Class III Label Continuation for BGS

by Zacks Equity Research

Orthofix (OFIX) pledges support for the continuation of the FDA's Class III status of BGS devices.

Zacks Equity Research

Orthofix (OFIX) Q4 Earnings Match Estimates, Margins Decline

by Zacks Equity Research

We are upbeat about the year-over-year revenue growth recorded by majority of Orthofix's (OFIX) key operating segments in Q4.

Zacks Equity Research

Orthofix (OFIX) Q4 Earnings Match Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 0.00% and -1.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orthofix (OFIX) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of -21.15% and -4.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

3D Printing Gaining Popularity: 3 MedTech Stocks to Watch

by Trina Mukherjee

In the near future, there is a probability of 3D-printed implantable organs becoming a reality, thereby increasing the number of lives saved.

Zacks Equity Research

Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down

by Zacks Equity Research

Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.

Zacks Equity Research

Orthofix (OFIX) Q2 Earnings Miss Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of -30.00% and 0.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Orthofix (OFIX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

Will MedTech Ease Investors' Concern & Outperform? 4 Picks

by Urmimala Biswas

Lower investment in MedTech might prove to be a concern, more so as gains within this space are staggering.

Zacks Equity Research

Orthofix (OFIX) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of -32.50% and -1.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orthofix (OFIX) Reports Encouraging M6-C Disc Study Results

by Zacks Equity Research

The primary goal of the study was to assess the safety and efficacy of Orthofix's (OFX) M6-C artificial cervical disc in comparison to ACDF treatment.

Zacks Equity Research

Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall

by Zacks Equity Research

Orthofix (OFIX) revenues across majority product lines witness year-over-year growth.

Zacks Equity Research

Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.